High doses of CBG impaired sustained attention in female rats but not males, despite marketing claims of cognitive enhancement

In rats given oral CBG at doses up to 600 mg/kg, females showed attention deficits at the highest doses while males were unaffected, and females had significantly higher blood levels of CBG than males.

Moore, Catherine F et al.·Pharmacology·2026·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-08504Animal StudyPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBG at 300-600 mg/kg impaired sustained attention in female rats but not males. CBG did not affect motivation or working memory in either sex. Females had significantly higher circulating CBG plasma levels than males after the same oral dose.

Key Numbers

Doses: 30-600 mg/kg oral. Attention deficits at 300-600 mg/kg in females only. No effects on motivation or working memory. Females had significantly higher plasma CBG levels than males.

How They Did This

Male and female adult Sprague Dawley rats received oral CBG (30-600 mg/kg) or vehicle before testing on rodent psychomotor vigilance (attention), progressive ratio responding (motivation), and spontaneous alternation (working memory). Blood collected 60 minutes post-administration for plasma CBG levels.

Why This Research Matters

CBG is increasingly marketed as a cognitive enhancer for focus and attention. This is the first controlled study to test those claims, and it found the opposite: high-dose CBG impaired attention in females.

The Bigger Picture

The cannabis supplement market makes unsubstantiated cognitive enhancement claims. This study shows minor cannabinoids may have sex-specific effects and that higher doses do not necessarily mean better outcomes.

What This Study Doesn't Tell Us

Animal study; rat doses may not directly translate to human doses. Acute dosing only. The attention deficit was only at very high doses.

Questions This Raises

  • ?Why do females absorb more CBG?
  • ?Would lower, human-comparable doses also affect attention?
  • ?Could the sex difference be relevant to human CBG users?

Trust & Context

Key Stat:
Attention deficits at 300-600 mg/kg in females only; females had higher plasma CBG levels
Evidence Grade:
Well-controlled animal study with multiple behavioral measures and pharmacokinetic data, but rat findings require human confirmation.
Study Age:
2026 publication
Original Title:
High doses of orally administered cannabigerol produce deficits in sustained attention in female rats.
Published In:
Pharmacology, biochemistry, and behavior, 260, 174154 (2026)
Database ID:
RTHC-08504

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Does CBG improve focus and attention?

Despite marketing claims, this study found the opposite at high doses in female rats. No cognitive benefits were observed at any dose in either sex.

Why were females more affected?

Females had significantly higher CBG blood levels after the same dose, likely due to differences in metabolism or body composition.

Read More on RethinkTHC

Cite This Study

RTHC-08504·https://rethinkthc.com/research/RTHC-08504

APA

Moore, Catherine F; Bergeria, Cecilia L; Sempio, Cristina; Klawitter, Jost; Christians, Uwe; Weerts, Elise M. (2026). High doses of orally administered cannabigerol produce deficits in sustained attention in female rats.. Pharmacology, biochemistry, and behavior, 260, 174154. https://doi.org/10.1016/j.pbb.2026.174154

MLA

Moore, Catherine F, et al. "High doses of orally administered cannabigerol produce deficits in sustained attention in female rats.." Pharmacology, 2026. https://doi.org/10.1016/j.pbb.2026.174154

RethinkTHC

RethinkTHC Research Database. "High doses of orally administered cannabigerol produce defic..." RTHC-08504. Retrieved from https://rethinkthc.com/research/moore-2026-high-doses-of-orally

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.